VIDEO: Sitravatinib plus nivolumab does not offer OS benefit over docetaxel in NSCLC subset
Click Here to Manage Email Alerts
Healio spoke with Hossein Borghaei, DO, MS, about results from the SAPPHIRE trial presented at this year’s ESMO Congress.
“Unfortunately, we realized that for our patients who are being treated upfront with a combination of chemotherapy and immunotherapy, at the time of disease progression, their options are rather limited,” Borghaei, chief of thoracic medical oncology, professor of hematology/oncology, co-director of the Immune Monitoring Facility and the Gloria and Edmund M. Dunn chair in thoracic oncology at Fox Chase Cancer Center, told Healio. “Right now, chemotherapy with agents such as docetaxel plus ramucirumab (Cyramza, Eli Lilly & Co.) is the accepted standard of care.”
Therefore, researchers of the SAPPHIRE trial assessed the use of sitravatinib (Mirati Therapeutics) plus nivolumab (Opdivo, Bristol Myers Squibb) compared with docetaxel in patients with advanced nonsquamous non-small cell lung cancer — excluding EGFR, ROS1 or ALK alterations — who had initially benefitted from receiving a checkpoint inhibitor with or following platinum based chemotherapy and had subsequently experienced disease progression.
“Unfortunately, even though numerically the sitravatinib plus nivolumab arm had better overall survival, it did not meet statistical significance and, therefore, it is not something that’s going to be taken forward,” Borghaei said.
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts